Skip to main content

AbbVie Inc. Q3 FY2026 results

  • ABBV · NYSE
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$295.03+0.20%Close 13 Nov 2026 · Market value $524.5B

AbbVie Inc. reported revenue of $17.4 billion, up 10.3% from a year earlier, net income of $4.22 billion and diluted earnings per share of $2.37 against $0.10 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 30 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

AbbVie Inc. Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$17.40B$15.78B+10.3%
Gross profit$13.12B$10.47B+25.3%
Gross margin75.4%66.4%+9.0 pts
Operating income$6.27B$1.90B+229%
Operating margin36.0%12.1%+23.9 pts
Net income$4.22B$186.0M+2168%
Diluted EPS$2.37$0.10+2270%
Operating cash flow$7.61B$7.02B+8.3%
Capital expenditure$301.0M$381.0M−21.0%
Free cash flow$7.30B$6.64B+10.0%

Operating KPIs for the quarter

AbbVie Inc. operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Skyrizi revenue$5.8Bup 22.7%
Rinvoq revenue$2.7Bup 23.9%
Botox Therapeutic revenue$1.1Bup 9.6%
Vraylar revenue$1.1Bup 14.3%
Venclexta revenue$803.0Mup 10.6%
Humira revenue$683.0Mdown 31.2%
Botox Cosmetic revenue$669.0Mup 5.0%
Imbruvica revenue$522.0Mdown 26.1%
Ubrelvy revenue$449.0Mup 26.8%
Qulipta revenue$398.0Mup 38.2%
Creon revenue$361.0Mdown 1.9%
Vyalev revenue$286.0Mup 107.2%
Mavyret revenue$265.0Mdown 15.1%
Elahere revenue$224.0Mup 31.8%
Juvederm Collection revenue$222.0Mdown 12.3%
Epkinly revenue$108.0Mup 56.5%
Immunology revenue$9.2Bup 16.2%
Neuroscience revenue$3.4Bup 19.3%
Oncology revenue$1.7Bup 0.8%
Aesthetics revenue$1.2Bdown 1.4%

Earlier quarters

AbbVie Inc. results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$17.40B+10.3%$2.37
Q2 FY202630 Jun 2026$16.99B+10.2%$2.03
Q1 FY202631 Mar 2026$15.00B+12.4%$0.39
Q4 FY202531 Dec 2025$16.62B+10.0%$1.02
Q3 FY202530 Sep 2025$15.78B+9.1%$0.10
Q2 FY202530 Jun 2025$15.42B+6.6%$0.52
Q1 FY202531 Mar 2025$13.34B+8.4%$0.72
Q4 FY202431 Dec 2024$15.10B+5.6%−$0.02

More on AbbVie Inc.: financial statements · revenue · earnings per share

ABBV's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.